Background. Contemporary cardiovascular practice relies increasingly on thrombolysis as a therapeutic modality. Its optimal use requires prompt, noninvasive delineation of thrombotic occlusion in arterial beds and rapid detection of reocclusion after initially successful thrombolysis.
Methods and Results. We have been developing an approach to noninvasively image thrombi in which plasminogen-activating properties of tissue-type plasminogen activator (t-PA) are attenuated by treatment with D-Phe-L-Pro-L-Arg-chloromethyl ketone (PPACK) and have shown that the inactive t-PA avidly and promptly binds to clots in vitro. In the present study, we conjugated this material to a residualizing label, radioiodinated dilactitol tyramine (*I-DLT), and characterized the potential use of the inactivated, conjugated t-PA as a radiopharmaceutical for imaging thrombi in vivo. The approach developed requires not only avid binding of the tracer to thrombi but also rapid clearance from plasma and a lack of prompt release of radiolabeled degradation products from the liver. The rapid clearance of unaltered or PPACK-treated t-PA was not influenced by conjugation to *I-DLT, but the release of radioiodinated degradation products into plasma after injection of *I-DLT-conjugated t-PA was markedly less than release of degradation products of directly radioiodinated t-PA. When 131i-DLT-PPACK-t-PA was infused for 15 minutes intravenously after a bolus injection of 20% in dogswith coronary, pulmonary, or carotid artery thrombi, clearance was rapid. Mean ± SEM thrombus-to-blood ratios of radioactivity were high, ranging from 37+9:1 and 2.8±0.6:1 with carotid thrombi formed concomitantly or approximately 30 minutes before infusion of tracer, respectively, to 35:1 for concomitantly formed coronary thrombi, 42±7:1 and 8.1±0.8:1 for concomitantly formed and preformed pulmonary thrombi, respectively, and 18:1 for a preformed femoral artery thrombus. Thrombi were detectable by planar gamma scintigraphy even though image quality was affected adversely by low concentrations of radioactivity that in aggregate composed a relatively large amount of radioactivity in underlying and overlying tissues. This limitation was overcome by tomographicimaging, which was used to detect both femoral and pulmonary thrombi.
Conclusions. Use of enzymatically inactivated t-PA coupled to a residualizing label permits rapid detection and localization of thrombi in vivo. (Circulation 1992; 85:288-297) T N hrombolysis is being used increasingly as priwith thrombolytic drugs (-15%) requires rapid nonmary therapy for several thromboembolic invasive detection to facilitate decisions critical in disorders. Its widespread implementation management.' Several radiopharmaceutical candicombined with the relatively high incidence of early dates have been evaluated as potential clot-imaging thrombotic reocclusion in a substantial minority of agents, including`M I-labeled fibrinogen,2 99mTc-lapatients with acute myocardial infarction treated beled plasmin,3 "'I-abeled plasminogen,4 13l11
From the Cardiovascular Division (J.M.O., J.H., A.D., S.R.B., labeled urokinase,5 and 131-and '9mTc-labeled streptokinase.67 However, none has exhibited sufficient sensitivity and specificity.`1In-labeled platelets provide specificity but require isolation and labeling of autologous platelets in each case. Furthermore, the long residence time of platelets in blood requires use of a second tracer to correct for radioactivity associated with circulating platelets.8 Radiolabeled antibodies to platelet membrane proteins9-11 and to fibrin12,13 are being evaluated, but their practical usefulness remains to be determined.
Tissue-type plasminogen activator (t-PA) binds to thrombi in the fibrin domain in interstices and on luminal surfaces of thrombi.14 t-PA is cleared rapidly from plasma with an a-phase half-life in dogs of approximately 2 minutes.1516 Accordingly, its properties are attractive for imaging thrombi. UnfortuSee p 382
nately, as was evident in studies with "`In-labeled t-PA,17 the serine protease activity leads to lysis of the thrombus being imaged18 and limits image quality obtainable with radiolabeled native t-PA. Furthermore, release of radiolabeled degradation products into the blood after rapid clearance of t-PA and hepatic catabolism degrades image quality by increasing the ratio of radioactivity in blood compared with that in the thrombus.
To overcome those difficulties, we prepared enzymatically inactive t-PA and conjugated it to a residualizing radiolabel that remains entrapped at the site of catabolism. t-PA was inactivated irreversibly with D-Phe-L-Pro-L-Arginyl-chloromethyl ketone (PPACK).'9 Enzymatically inactive t-PA was conjugated to radioiodinated dilactitol tyramine (*I-DLT20) to was diluted to 20 ml with saline. The tracer was injected as a bolus (20% of total radioactivity) followed by the remainder given as a continuous infusion (5% of total radioactivity per minute). Aliquots of blood were obtained at selected intervals after bolus injection to monitor clearance of radioactivity from the circulation. Lidocaine (1 mg/kg) was administered as a bolus followed by a continuous infusion of 50 ,ug/kg/min to prevent malignant ventricular arrhythmia after placement of copper coils in coronary arteries. In some experiments, clots were formed with cotton threads inserted into the target vessel with a guide wire. The presence of total or partial occlusion was determined by angiography at repeated intervals.
Imaging. Images comprising 50,000-250,000 counts were obtained with a large-field planar gamma camera fitted with a low-or medium-energy parallel-hole collimator for 123J and 311, respectively. Energy discriminators were set at the peak of the energy spectrum for each isotope with a 20% window. For tomographic studies, single-photon emission computed tomography (SPECT) was performed with a low-energy collimator for detection of 123J. 99mTc-labeled red blood cells were subsequently injected in some studies to permit visualization of the vasculature. Images were interpreted by a nuclear medicine physician at the Mallinckrodt Institute of Radiology (Dr. Henry Royal).
Assay of radioactivity in tissue and blood. Results Conjugation of Radioiodinated DLT to PPACK4-PA *I-DLT was conjugated to proteins via reductive amination, a process that exhibits a predilection for primary amines. Stock solutions of the t-PA were in buffer containing high concentrations of arginine to enhance solubility. Accordingly, conjugation of *I-DLT to the unprocessed material initially led to unacceptable efficiencies of less than 1%. To circumvent this difficulty, t-PA was dialyzed against either imidazole or KSCN under conditions that maintained t-PA in solution in a concentration as high as 50 mg/ml and permitted efficient radiolabeling with *I-DLT.
Binding of t-PA to Clots
Reductive amination of *I-DLT to proteins results in formation of adducts to e-amino groups of lysine residues. Because specific lysine residues of t-PA may participate in the binding of the protein to fibrin, the binding of the radiolabeled material to clots formed in vitro was characterized to determine whether radiolabeling impaired binding. As illustrated in Figure 1 , conjugation of 125I-DLT to PPACK-t-PA did not result in any significant change in the binding affinity to preformed clots compared with that of the directly radioiodinated PPACK-t-PA.18
To determine whether binding of 1251-DLT-PPACK-t-PA to clots was influenced markedly by the interval between formation of the clot and exposure to the radiolabeled t-PA derivative, additional clot-binding assays were performed in vitro. The interval between the initiation of clot formation and the introduction of 125I-DLT-PPACK-t-PA was varied from 0 to 4 hours. Binding was greatest when 125I-DLT-PPACK-t-PA was introduced at the time of clot formation, undoubtedly because of optimal access of the tracer to fibrin throughout the evolving clot. However, binding remained considerable even when the radiolabel was introduced 30 minutes after onset of clot formation and for longer intervals throughout the 4-hour interval studied (Figure 2 ).
Clearance of *I-DLT-PPACK-t-PA in Rabbits Kinetics of clearance from plasma of radioiodinated t-PA were characterized in rabbits to determine whether the conjugation of *I-DLT to t-PA influenced removal of t-PA from the vascular compartment. Intravenous administration of directly radioiodinated t-PA was followed by initial, rapid clearance with the concentration of radioactivity in plasma reaching a nadir in 15 minutes. Thereafter, concentrations of radioactivity in plasma increased slightly before reaching a plateau ( Figure 3A) . In contrast to the concentration of radioactivity in aliquots of plasma, radioactivity in the fractions precipitable by TCA continued to decline. Conjugation of PPACK to directly radioiodinated t-PA did not appreciably alter clearance or the appearance of TCA-soluble radioactivity ( Figure 3B ). In contrast to either '25I-t-PA or 1251-PPACK-t-PA, radioactivity in aliquots of plasma after intravenous injection of 1251-DLT-PPACKt-PA declined continuously over the 2-hour interval of observation. In addition, differences between the amount of radioactivity present in plasma compared with that in the TCA-precipitable fractions were minimal ( Figure 3C ). Thus, clearance of 125I-DLT-PPACK-t-PA from plasma in vivo was considerably less distorted by release into the plasma of radiolabeled degradation products compared with the use of 1251-t-PA and 1251-PPACK-t-PA.
Only approximately 5% of the injected dose of either 1251-t-PA or 125I-PPACK-t-PA was present in the liver after 2 hours. In contrast, 73+±3% of the injected radioactivity with 125I-DLT-PPACK-t-PA was present in the liver at corresponding intervals as judged from assay of radioactivity in excised samples of liver ( Figure  4 ). This observation is consistent with retention in the liver of a large fraction of the residualizing label after hepatic uptake of '25I-DLT-PPACK-t-PA. Points represent all data acquired from each of 13 dogs.
Results from individual animals are represented by specific symbols. Curve represents best fit of biexponential clearance curve after termination of infusion.
Clearance of *I-DLT-PPACK-t-PA in Dogs
*I-DLT-PPACK-t-PA was injected as a bolus followed by a 15-minute infusion into the femoral vein of anesthetized dogs. The initial bolus contained 20% of the total mass of protein injected. Concentrations of radioactivity in plasma decreased rapidly after cessation of the infusion. The concentration in plasma had declined within 1 hour to only 19% of the initial, maximal concentration ( Figure 5 ). Accordingly, imaging commenced 36-74 minutes after the onset of infusion of the tracer. As in studies in rabbits, clearance was biexponential in dogs.
Clot-to-Blood and Clot-to-Tissue Ratios of Radioactivity Clot-to-blood ratios of radioactivity were determined 1-3 hours after completion of *JIDLT-PPACK-t-PA infusions in dogs. Clot-to-blood ratios of radioactivity were consistently high with clots formed while tracer was being infused, as shown in Table 1 . Thrombi in coronary arteries exhibited the highest values, probably related in part to their diminutive size. Clots formed in the pulmonary and carotid arteries were consistently larger than those formed in the coronary arteries. In clots formed before infusion of tracer, the clot-to-blood average ratios ranged from 2.8:1 to 18:1 (Table 2) . Higher values were induced systematically as our technique for producing an optimal amount of chemically homogenous tracer improved with experience and with subtle modifications, leading to the final protocol described in "Methods."
In addition to the high ratios of radioactivity in clots compared with that in blood, ratios of radioactivity in clots compared with that in adjacent and surrounding tissue were also high, as shown in studies Figure 6 , carotid thrombi with high clot-to-blood ratios (27:1) could be readily delineated with this approach. Carotid artery clots were imaged in each of three dogs in which thrombosis was initiated at approximately the same time as the onset of tracer infusion.
To determine whether imaging was possible with introduction of tracer after clots had been formed, additional experiments were performed with induction of carotid and femoral thrombosis 15-70 minutes before infusion of tracer. As can be seen in Figure 7 , good visualization was accomplished even though clot-to-blood ratios of radioactivity were lower (18:1) with the preformed clot, presumably because of a decreased amount of fibrin surface being available for interaction with plasma as the clot coalesces and contracts as well as because of decreased delivery of label to clot. Pulmonary artery thrombi were initially much larger than carotid thrombi as evident from angiography. However, because of well-appreciated high fibrinolytic activity of canine blood in vivo, considerable dissolution of pulmonary thrombi occurred during the course of imaging. The magnitude of dissolution was generally the same, regardless of whether enzymatically inactive radioiodinated dilactitol tyramine-D-Phe-L-Pro-L-Arg-chloromethyl ketone-tissue-type plasminogen activator (*I-DLT-PPACK-t-PA) was infused. In additional experiments in vitro (data not shown), *I-DLT-PPACK-t-PA did not inhibit lysis of Chandler tube human whole blood clots by exogenous t-PA.
In several animals, more than one clot was induced and characterized.
With the final protocol developed as described in the text, two dogs were imaged by single-photon emission computed tomography. In both of these, the induced clot was visualized.
*A total of 10 dogs were studied. In some, clots were induced in more than one vascular bed. Although background radioactivity in surrounding tissue was not diminished, the use of SPECT circumvented its impact by virtue of tomographic delineation of the clot from multiple angles of view.
The conditions used in the present study were initially selected to be optimal in that the tracer was given at the time of clot formation. However, the binding of *I-DLT-PPACK-t-PA to preformed clots was shown to be avid in vitro, and difficulties were not anticipated with imaging in vivo. Although clotto-blood ratios were diminished in vivo with preformed clots, they remained high enough to permit successful imaging of clots in this portion of the study.
In our preparations both totally and partially occluding clots were imaged. Total occlusion would, of course, limit the amount of tracer that could be taken up by the clot because only the end surfaces would be sufficiently exposed to the tracer. Clinically, either partial occlusion or intermittent partial recanalization would be expected to expose a greater surface area of thrombus to the tracer, resulting in higher clot-to-blood ratios. Our 
